《若干措施》提出，优化商业健康保险服务体验。研究利用医保和第三方信息平台等多种渠道，提供政 策宣传、产品供需对接、线上投保、订单管理、权益查询和理赔服务。鼓励商业保险公司与医疗机构、 体检机构、康复护理机构等合作，提供健康体检、疾病预防、慢病管理等综合服务，发挥健康管理风险 减量作用。 《若干措施》提出，拓展商业健康保险服务网络。依托现有医保管理优势，支持商业保险公司与各级各 类定点医疗机构开展深度合作与高效对接，进一步扩大和优化商业健康保险服务覆盖网络，有效降低商 业保险公司与不同医疗机构的对接与运营成本，提升服务可及性与便利性。 北京商报讯（记者 胡永新）2月12日，北京市医保局、北京金融监管局等部门联合发布《北京市支持商 业健康保险高质量发展的若干措施》（以下简称《若干措施》），在提升商业健康保险服务能力方面， 《若干措施》提出，研究放宽医保个人账户使用范围。研究参保职工可使用医保个人账户资金为本人及 家庭成员购买符合条件的商业健康保险产品。鼓励用人单位利用补充医疗保险等优惠政策（补充医疗保 险费的提取额在本用人单位上一年职工工资总额4%以内部分从成本中列支），购买商业补充医疗保 险。 《若干措施》提出 ...

Group 1: Monetary Policy - The People's Bank of China (PBOC) will continue to implement a moderately accommodative monetary policy in 2026, focusing on promoting stable economic growth and reasonable price recovery [1] - On January 23, 2026, the PBOC will conduct a 900 billion MLF operation with a one-year term to maintain ample liquidity in the banking system [2] Group 2: Health Insurance Development - The Ministry of Commerce and nine other departments have issued opinions to support the development of commercial health insurance products tailored for the pharmaceutical retail sector, aiming to create a payment guarantee system [3] - The initiative encourages collaboration between commercial health insurance and basic medical insurance, which is significant for reducing patient medication costs and improving the public health system [3] Group 3: Market Reactions - A-share gold concept stocks experienced a general decline, with notable drops in companies such as Xiaocheng Technology and Shandong Gold, likely influenced by recent fluctuations in international gold prices and a stronger dollar [4] Group 4: U.S. Federal Reserve Leadership - U.S. President Trump has hinted at a decision regarding the next Federal Reserve Chair, which could have significant implications for U.S. monetary policy and the global economic landscape [5]

Group 1: Space Tourism - ChuanYueZhe Company has booked over 20 space tourists and plans to achieve its first manned flight by 2028 [1] - The first batch of space tourists includes notable figures such as Li Lihua, Qiu Heng, Wang Jing, and Fu Zhekuan, along with a silicon-based life form [1] Group 2: Monetary Policy - The People's Bank of China, led by Governor Pan Gongsheng, indicates that there is still room for interest rate cuts and reserve requirement ratio reductions in 2026 [2] - The central bank aims to maintain a stable economic growth environment and ensure that monetary policy supports the "14th Five-Year Plan" [2] Group 3: Gold Price Forecast - Goldman Sachs has raised its gold price target for December 2026 from $4,900 to $5,400 per ounce, citing increased diversification into gold by the private sector as a hedge against global uncertainties [2] Group 4: Semiconductor Industry - ASMPT announced the divestiture of its SMT business to focus on its core semiconductor sector, which is seen as a move to clarify the value of its semiconductor assets [2] Group 5: Autonomous Vehicles - CaoCao Mobility plans to deploy 100,000 fully customized Robotaxis by 2030, with pilot operations already underway for its second-generation Robotaxi [3] Group 6: Cryptocurrency and AI - BitGo Holdings raised $212.8 million in its IPO, setting a precedent for digital asset companies in 2026 [4][5] - Binance founder Zhao Changpeng expressed optimism about the future of tokenization, payments, and AI, predicting that cryptocurrencies will become the native currency for AI agents [6] Group 7: Health Insurance - Nine Chinese departments, including the Ministry of Commerce, are promoting the development of commercial health insurance products tailored for the pharmaceutical retail sector [7] Group 8: International Relations - The Chinese Ministry of Foreign Affairs expressed serious concerns over the EU's classification of certain Chinese companies as high-risk suppliers, emphasizing the importance of fair treatment in international trade [8] Group 9: AI Regulation - South Korea's AI Basic Law, effective January 22, aims to support the healthy development of the AI industry while mitigating potential risks associated with AI technologies [9]

Core Viewpoint - The Ministry of Commerce, along with eight other departments, has issued an opinion aimed at promoting high-quality development in the pharmaceutical retail industry through 18 specific measures across five dimensions, focusing on enhancing professional services, health promotion, emergency supply, industry structure optimization, and industry order regulation [1] Group 1: Improvement of Pharmaceutical Services - The opinion emphasizes the promotion of prescription circulation to enhance the purchasing experience, advocating for the improvement of external prescription circulation mechanisms and the optimization of settlement rules [3] - It encourages the establishment of electronic prescription circulation platforms and the integration of retail pharmacies with medical institutions to facilitate prescription transfers [3] - The opinion aims to optimize the settlement methods between medical insurance funds and retail pharmacies, thereby improving efficiency and resource allocation [3] Group 2: Industry Structure Optimization - The opinion encourages horizontal mergers and acquisitions among pharmaceutical retail enterprises and aims to streamline the licensing process for integrated pharmacies [4] - It supports the integration of supply chains through mergers and acquisitions in the wholesale sector, promoting a unified development of wholesale and retail [4] - The opinion is expected to drive industry consolidation and upgrade, leading to the formation of large-scale, competitive pharmaceutical retail enterprises [5] Group 3: Price Regulation and Consumer Protection - The opinion advocates for collaboration between pharmaceutical manufacturers and large distribution companies to standardize drug pricing systems and promote fair competition across regions [5] - It encourages the sale of innovative drugs and reference preparations through retail channels and the establishment of price monitoring tools for consumers [6] - The promotion of price comparison tools for insured drugs is seen as crucial for ensuring market price regulation and protecting consumer rights [6]

Group 1 - The Ministry of Commerce and nine other departments have jointly issued opinions to promote the high-quality development of the pharmaceutical retail industry, focusing on centralized procurement, commercial insurance systems, and supporting mergers and acquisitions among retail pharmacies [1][2] - The opinions encourage retail pharmacies to participate in centralized procurement and to consolidate purchasing demands to enhance bargaining power, while also ensuring supply security from manufacturers [1] - A commercial insurance payment guarantee system is proposed to support the development of health insurance products tailored for retail pharmacy scenarios, aiming to reduce patient payment burdens [1][2] Group 2 - The pharmaceutical retail industry is undergoing a transformation from scale expansion to quality competition, with the market size reaching 929.3 billion yuan in 2023, reflecting a 6.5% year-on-year growth, although the growth rate has significantly slowed [3] - The number of retail pharmacies is projected to decline from 706,000 in Q3 2024 to 699,000 in Q1 2025, influenced by industry slowdown, online competition, and regulatory impacts [3] - Leading chain enterprises are expected to gain competitive advantages over smaller pharmacies due to their cost management, operational capabilities, and financial strength, leading to increased industry concentration and chain rate [3]

Core Viewpoint - The document outlines the government's initiative to promote high-quality development in the pharmaceutical retail industry through collaboration with commercial health insurance and the introduction of innovative insurance products to meet diverse consumer needs [1][2]. Group 1: Collaboration with Insurance - The government encourages the development of commercial health insurance products that align with pharmaceutical retail scenarios to meet the diverse protection needs of the public [1]. - It supports the establishment of risk-sharing and efficient payment mechanisms between pharmaceutical retail enterprises and commercial insurance institutions, specifically for high-value drugs and medical devices, to reduce patient payment burdens [1]. Group 2: Innovative Insurance Products - The document promotes the development of commercial health insurance products that include health management and elder care services [1]. - It also encourages insurance institutions to create liability insurance for drone delivery of medical supplies and equipment [2].

Core Viewpoint - The Ministry of Commerce and nine other departments have issued opinions to promote the high-quality development of the pharmaceutical retail industry, focusing on the establishment of a commercial insurance payment guarantee system [1] Group 1: Commercial Insurance Development - The initiative aims to guide the collaborative development of commercial health insurance and basic medical insurance [1] - It encourages insurance institutions to develop commercial health insurance products tailored to the pharmaceutical retail scenario, addressing diverse protection needs of the public [1] - The plan supports the launch of commercial health insurance products that include health management and elder care services [1] Group 2: Risk Sharing Mechanism - The initiative supports the establishment of a risk-sharing and efficient payment collaboration mechanism between pharmaceutical retail enterprises and commercial insurance institutions, particularly for high-value drugs and medical devices [1] - This mechanism is designed to effectively reduce the financial burden on patients [1]

Investment Rating - The report assigns an "Accumulate" rating for the industry [1] Core Insights - The National Medical Security Work Conference emphasizes the continuation of optimizing centralized procurement policies in 2026, promoting the development of maternity insurance and long-term care insurance, and leveraging strategic purchasing to support the innovative drug industry [3] - The report highlights the importance of commercial health insurance in complementing basic medical insurance and encourages investment in innovative drug development [5] Summary by Sections National Medical Security Work Conference - The conference held on December 13, 2025, summarized the work during the "14th Five-Year Plan" period and outlined the tasks for 2026, including support for commercial health insurance and the establishment of a multi-tiered medical security system [5] - The National Medical Security Bureau will promote the inclusion of flexible employment workers and migrant workers in maternity insurance coverage, aiming for "no out-of-pocket" expenses for childbirth within policy limits [5] Support for Innovative Drug Development - The report discusses the strategic role of medical insurance in fostering healthy competition and differentiated innovation within the pharmaceutical industry [5] - It mentions the implementation of new rounds of national centralized procurement for drugs and high-value medical consumables, aiming to enhance the efficiency of company receivables [5]

Core Viewpoint - Shanghai has introduced a new set of measures aimed at enhancing the development of commercial health insurance and supporting innovation in the biopharmaceutical industry, focusing on improving the multi-payment mechanism and data sharing among medical institutions, pharmaceutical companies, and insurance providers [1][2]. Group 1: Policy Measures - The new measures, referred to as "New 18 Measures," aim to strengthen the collaboration between basic medical insurance and commercial health insurance, addressing core issues related to the application of innovative medical devices and patient payment [1][3]. - The document emphasizes the importance of data sharing among medical institutions, pharmaceutical companies, and commercial insurance companies to facilitate product development and pricing [2][3]. - The measures encourage the development of innovative commercial health insurance products that can expand basic coverage and provide reasonable pricing [3][4]. Group 2: Data Sharing and Collaboration - The new policies establish a framework for a data-sharing mechanism among medical, insurance, and pharmaceutical sectors, ensuring data security and privacy while expanding the scope of data available for product design and risk assessment [2][3]. - Insurance companies are encouraged to access historical health data in a secure environment to support the development of targeted insurance products [3][4]. - The measures aim to enhance the interaction between insurance institutions and the biopharmaceutical industry, promoting collective procurement and payment mechanisms to improve the accessibility and affordability of innovative medical devices [7]. Group 3: Targeted Insurance Products - The new measures support the development of various health insurance products, including group insurance, special disease insurance, and high-end medical services, tailored to specific populations such as the elderly and those with pre-existing conditions [2][5]. - The policies also propose using personal account balances for purchasing insurance products, thereby facilitating access to health insurance for a broader audience [5][6]. - The measures highlight the importance of group insurance products, which do not differentiate based on pre-existing conditions, as a key growth area for the health insurance industry [6]. Group 4: Financial and Operational Support - Shanghai aims to address fundamental issues affecting the commercial health insurance sector, such as funding challenges and customer acquisition difficulties, through multi-departmental collaboration [4][6]. - The new measures propose financial incentives for employers to purchase group health insurance for employees, allowing for shared premium payments and tax deductions [6][7]. - The integration of commercial health insurance with basic medical insurance is emphasized, with a focus on optimizing claims processes and expanding the coverage of innovative medical devices [6][7].

Group 1 - The core viewpoint of the article is the issuance of measures to promote the high-quality development of commercial health insurance, which aims to support innovation in the biopharmaceutical industry [1] - The measures emphasize the enhancement of the application of medical insurance data in commercial insurance settlements, optimizing the synchronous settlement model between medical insurance and commercial insurance [1] - The initiative includes the collaboration with the "Shanghai Insurance Code" platform to improve direct compensation service processes and expand access to more medical institutions and commercial health insurance products [1] Group 2 - The measures aim for full coverage of secondary and tertiary hospitals and explore extending direct compensation services to special departments and international departments of hospitals [1] - The "Shanghai Insurance Code" will be improved to enhance its "one code for all compensation" functionality, utilizing blockchain technology to build an active compensation system between medical insurance and commercial insurance [1] - The initiative also focuses on ensuring the traceability of the entire process through authorized information, transaction records, and claims results being recorded on the blockchain, thereby increasing the transparency and efficiency of the claims service [1]